Nadolol: Supply issue and brand change

Supply issue Brand change Active

Nadolol is changing from Apo-Nadolol to Nadolol BNM. The change will happen in October 2021.

Apo-Nadolol 40 mg running low 

We understand that stock of the Apo-Nadolol 40 mg (pharmacode 787493) tablets are likely to be exhausted within the supply chain by early-mid October. 

BNM Nadolol will likely be available by late October. In the meantime, there is ample stock of Apo-Nadolol 80 mg tablets (pharmacode 787515). The Apo-Nadolol 80 mg tablets are scored.

About BNM Nadolol 

Apo-Nadolol was supplied by Apotex who have left the New Zealand market. We have secured a new supplier of nadolol Boucher & Muir. BNM Nadolol will be listed in the Schedule from 1 October 2021 and will be available by mid to late October. 

Read the full decision to fund BNM Nadolol

BNM Nadolol is not currently Medsafe approved. This means it will need to be prescribed and supplied in line with section 29 of the Medicines Act. We understand that Boucher & Muir are applying to Medsafe for approval.

Prescribing and supplying a medicine under section 29

Section 29 of the Medicines Act allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – e.g., doctors. 

We know supplying a medicine under section 29 is not ideal. In this case, however, the alternative would be for patients to have no nadolol. 

We apologise for any inconvenience this causes. 

Prescriber and pharmacist requirements for section 29 medicines – Medsafe website(external link)

What patients need to know about section 29 medicines – Health Navigator website(external link)

Schedule listing information

1 October 2021: Nadolol (Nadolol BNM) tab

  • 40 mg (pharmacode 2621118) / pack size 100 / price $19.19
  • 80 mg (pharmacode 2621126) / pack size 100 / price $30.39
  • Wastage claimable.

1 March 2022: Apo-Nadolol delisted

Schedule listing for nadolol(external link)

Who to contact 

If you have questions about medicine funding, email enquiry@pharmac.govt.nz

BNM Nadolol is not currently Medsafe approved. This means it will need to be prescribed and supplied in line with section 29 of the Medicines Act. We understand that Boucher & Muir are applying to Medsafe for approval.

Prescribing and supplying a medicine under section 29

Section 29 of the Medicines Act allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – e.g., doctors. 

We know supplying a medicine under section 29 is not ideal. In this case, however, the alternative would be for patients to have no nadolol. 

We apologise for any inconvenience this causes. 

Prescriber and pharmacist requirements for section 29 medicines – Medsafe website(external link)

What patients need to know about section 29 medicines – Health Navigator website(external link)

Schedule listing information

1 October 2021: Nadolol (Nadolol BNM) tab

  • 40 mg (pharmacode 2621118) / pack size 100 / price $19.19
  • 80 mg (pharmacode 2621126) / pack size 100 / price $30.39
  • Wastage claimable.

1 March 2022: Apo-Nadolol delisted

Schedule listing for nadolol(external link)

Who to contact 

If you have questions about medicine funding, email enquiry@pharmac.govt.nz